External broker reports(aggregated public sources), Taylor Collison

Taylor Collison

Taylor Collison is a leading financial services firm, providing advice & wealth creation strategies to private & institutional investors and corporate clients throughout Australia. Content available is external broker reports authored by a third party outside the Smartkarma network and has been aggregated by an online aggregator through publicly available sources and is displayed by Smartkarma in this format for user's convenience and general informational purposes only. Content does not constitute investment or financial advice and Smartkarma makes no representation or warranty regarding its accuracy or contents. Original third party author retains all copyright and other proprietary rights in the content. Access or use of third party links not controlled by Smartkarma are at the user's own risk.

External broker reports(aggregated public sources)

Equity Bottom-Up

<ul><li>GSS is approaching a potentially transformative milestone, as the FDA review of its 510(k) application for clearance to market its EasyScreen gastrointestinal parasite (GIP) test kit in the US enters the final stage.</li><li>We understand that GSS submitted its response to the FDA’s Additional Information request late last month, in line with guidance that it expected to submit its response to the FDA queries during April.</li><li>We see a high likelihood that the FDA will issue its decision before the end of May, in line with its review timeline goals</li></ul><p><em>Content is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.</em></p>

GSS is approaching a potentially transformative milestone, as the FDA review of its 510(k) application for clearance to market its EasyScreen gastrointestinal parasite (GIP) test kit in the US enters the final stage.We understand that GSS submitted its response to the FDA’s Additional Information request late last month, in line with guidance that it expected to submit its response to the FDA queries during April.We see a high likelihood that the FDA will issue its decision before the end of May, in line with its review timeline goalsContent is external broker report sourced from online content aggregator through publicly available sources and is displayed below for general informational purposes only. Refer full disclaimer below.

Genetic Signatures (GSS) - FDA Review Nearing the Finish Line